These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 19595855)

  • 1. Synaptic targeting by A beta oligomers (ADDLS) as a basis for memory loss in early Alzheimer's disease.
    Klein WL
    Alzheimers Dement; 2006 Jan; 2(1):43-55. PubMed ID: 19595855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why Alzheimer's is a disease of memory: the attack on synapses by A beta oligomers (ADDLs).
    Viola KL; Velasco PT; Klein WL
    J Nutr Health Aging; 2008 Jan; 12(1):51S-7S. PubMed ID: 18165846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking the Interaction between EphB2 and ADDLs by a Small Peptide Rescues Impaired Synaptic Plasticity and Memory Deficits in a Mouse Model of Alzheimer's Disease.
    Shi XD; Sun K; Hu R; Liu XY; Hu QM; Sun XY; Yao B; Sun N; Hao JR; Wei P; Han Y; Gao C
    J Neurosci; 2016 Nov; 36(47):11959-11973. PubMed ID: 27881781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADDLs and the signaling web that leads to Alzheimer's disease.
    Krafft GA; Klein WL
    Neuropharmacology; 2010; 59(4-5):230-42. PubMed ID: 20650286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synaptotoxic amyloid-β oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease?
    Klein WL
    J Alzheimers Dis; 2013; 33 Suppl 1():S49-65. PubMed ID: 22785404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid flirting with synaptic failure: towards a comprehensive view of Alzheimer's disease pathogenesis.
    Marcello E; Epis R; Di Luca M
    Eur J Pharmacol; 2008 May; 585(1):109-18. PubMed ID: 18377893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease.
    Lacor PN; Buniel MC; Furlow PW; Clemente AS; Velasco PT; Wood M; Viola KL; Klein WL
    J Neurosci; 2007 Jan; 27(4):796-807. PubMed ID: 17251419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss.
    Gong Y; Chang L; Viola KL; Lacor PN; Lambert MP; Finch CE; Krafft GA; Klein WL
    Proc Natl Acad Sci U S A; 2003 Sep; 100(18):10417-22. PubMed ID: 12925731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synaptic degeneration in Alzheimer's disease.
    Arendt T
    Acta Neuropathol; 2009 Jul; 118(1):167-79. PubMed ID: 19390859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers.
    De Felice FG; Vieira MN; Bomfim TR; Decker H; Velasco PT; Lambert MP; Viola KL; Zhao WQ; Ferreira ST; Klein WL
    Proc Natl Acad Sci U S A; 2009 Feb; 106(6):1971-6. PubMed ID: 19188609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting generation of antibodies specific to conformational epitopes of amyloid beta-derived neurotoxins.
    Lambert MP; Velasco PT; Viola KL; Klein WL
    CNS Neurol Disord Drug Targets; 2009 Mar; 8(1):65-81. PubMed ID: 19275637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ROCK, PAK, and Toll of synapses in Alzheimer's disease.
    Salminen A; Suuronen T; Kaarniranta K
    Biochem Biophys Res Commun; 2008 Jul; 371(4):587-90. PubMed ID: 18466762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformation-dependent single-chain variable fragment antibodies specifically recognize beta-amyloid oligomers.
    Wang XP; Zhang JH; Wang YJ; Feng Y; Zhang X; Sun XX; Li JL; Du XT; Lambert MP; Yang SG; Zhao M; Klein WL; Liu RT
    FEBS Lett; 2009 Feb; 583(3):579-84. PubMed ID: 19162022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of amyloid-beta derived diffusible ligands (ADDLs) in Alzheimer's disease.
    Catalano SM; Dodson EC; Henze DA; Joyce JG; Krafft GA; Kinney GG
    Curr Top Med Chem; 2006; 6(6):597-608. PubMed ID: 16712494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid beta oligomers induce impairment of neuronal insulin receptors.
    Zhao WQ; De Felice FG; Fernandez S; Chen H; Lambert MP; Quon MJ; Krafft GA; Klein WL
    FASEB J; 2008 Jan; 22(1):246-60. PubMed ID: 17720802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reelin and apoE actions on signal transduction, synaptic function and memory formation.
    Rogers JT; Weeber EJ
    Neuron Glia Biol; 2008 Aug; 4(3):259-70. PubMed ID: 19674510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of ADDL--targeting small molecule drugs for Alzheimer's disease.
    Look GC; Jerecic J; Cherbavaz DB; Pray TR; Breach JC; Crosier WJ; Igoudin L; Hironaka CM; Lowe RM; McEntee M; Ruslim-Litrus L; Wu HM; Zhang S; Catalano SM; Goure WF; Summa D; Krafft GA
    Curr Alzheimer Res; 2007 Dec; 4(5):562-7. PubMed ID: 18220523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances on the understanding of the origins of synaptic pathology in AD.
    Lacor PN
    Curr Genomics; 2007 Dec; 8(8):486-508. PubMed ID: 19415125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of Alzheimer's diagnosis using semi-supervised distance metric learning with label propagation.
    Teramoto R
    Comput Biol Chem; 2008 Dec; 32(6):438-41. PubMed ID: 18789768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.